Opioid switching and rotation in primary care: implementation and clinical utility

References

• 1999 National Pain Survey. Available at: http://www.chiro.org/LINKS/FULL/1999_National_Pain_Survey.html [Last accessed 2009 June 02]
   Google Scholar
• Cosby AG, Hitt HC, Thornton-Neaves T, et al. Profiles of pain in Mississippi: results from the Southern Pain Prevalence Study. J Miss State Med Assoc 2005;46:301-9
   PubMedGoogle Scholar
• Lin JT, Mathew P. Cancer pain management in prisons: a survey of primary care practitioners and inmates. J Pain Symptom Manage 2005;29:466-73
   PubMed Web of Science ®Google Scholar
• Rolnick SJ, Jackson J, Nelson WW, et al. Pain management in the last six months of life among women who died of ovarian cancer. J Pain Symptom Manage 2007;33:24-31
   PubMed Web of Science ®Google Scholar
• Apfelbaum JL, Chen C, Mehta SS, et al. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003;97:534-40
   PubMed Web of Science ®Google Scholar
• Austrup ML, Korean G. Analgesic agents for the postoperative period. Opioids. Surg Clin North Am 1999;79:253-73
   PubMed Web of Science ®Google Scholar
• Brown AK, Christo PJ, Wu CL. Strategies for postoperative pain management. Best Pract Res Clin Anaesthesiol 2004;18:703-17
   PubMedGoogle Scholar
• Jain S, Datta S. Postoperative pain management. Chest Surg Clin N Am 1997;7:773-99
   PubMedGoogle Scholar
• World Health Organization. Cancer pain relief. Geneva, Switzerland: WHO Office of Publication; 1996
   Google Scholar
• American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum 2000;43:1905-15
   Google Scholar
• The use of opioids for the treatment of chronic pain. A consensus statement from the American Academy of Pain Medicine and the American Pain Society. Clin J Pain 1997;13:6-8
   PubMed Web of Science ®Google Scholar
• AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50:S205-24
   PubMed Web of Science ®Google Scholar
• Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med 2003;349:1943-53
   PubMed Web of Science ®Google Scholar
• Katz NP, Adams EH, Benneyan JC, et al. Foundations of opioid risk management. Clin J Pain 2007;23:103-18
   PubMed Web of Science ®Google Scholar
• Nicholson B, Passik SD. Management of chronic noncancer pain in the primary care setting. South Med J 2007;100:1028-36
   PubMed Web of Science ®Google Scholar
• Murtagh FE, Chai MO, Donohoe P, et al. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother 2007;21:5-16
   PubMedGoogle Scholar
• Mercadante S, Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 2006;32:304-15
   PubMed Web of Science ®Google Scholar
• Quang-Cantagrel ND, Wallace MS, Magnuson SK. Opioid substitution to improve the effectiveness of chronic noncancer pain control: a chart review. Anesth Analg 2000;90:933-7
   PubMed Web of Science ®Google Scholar
• Grilo RM, Bertin P, Scotto di Fazano C, et al. Opioid rotation in the treatment of joint pain. A review of 67 cases. Joint Bone Spine 2002;69:491-4
   PubMed Web of Science ®Google Scholar
• Cherny N, Ripamonti C, Pereira J, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 2001;19:2542-54
   PubMed Web of Science ®Google Scholar
• Riley J, Ross JR, Rutter D, et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 2006;14:56-64
   PubMed Web of Science ®Google Scholar
• Dahlstrom B, Tamsen A, Paalzow L, et al. Patient-controlled analgesic therapy, Part IV: pharmacokinetics and analgesic plasma concentrations of morphine. Clin Pharmacokinet 1982;7:266-79
   PubMed Web of Science ®Google Scholar
• Tamsen A, Hartvig P, Fagerlund C, et al. Patient-controlled analgesic therapy, Part II: Individual analgesic demand and analgesic plasma concentrations of pethidine in postoperative pain. Clin Pharmacokinet 1982;7:164-75
   PubMed Web of Science ®Google Scholar
• Tamsen A. Patient characteristics influencing pain relief. In: Harmer M, Rosen M, Vickers MD, eds. Patient-controlled Analgesia. Oxford: Blackwell Scientific Publications 1985:30-7
   Google Scholar
• Ashby M, Fleming B, Wood M, et al. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 1997;14:157-67
   PubMed Web of Science ®Google Scholar
• Aubrun F, Langeron O, Quesnel C, et al. Relationships between measurement of pain using visual analog score and morphine requirements during postoperative intravenous morphine titration. Anesthesiology 2003;98:1415-21
   PubMed Web of Science ®Google Scholar
• Greenfield S, Kravitz R, Duan N, et al. Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment. Am J Med 2007;120:S3-9
   PubMed Web of Science ®Google Scholar
• Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med 2001;7:201-4
   PubMed Web of Science ®Google Scholar
• Goldstein DB, Need AC, Singh R, et al. Potential genetic causes of heterogeneity of treatment effects. Am J Med 2007;120:S21-5
   PubMed Web of Science ®Google Scholar
• Quigley C. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev 2004; CD004847
   Google Scholar
• Coffey J. Legacy ID No. 2006P-0090, Docket No. 2006-P-0270, Immediately begin the phased removal from the market of propoxyphene (Darvon) and all propoxyphene-containing products such as Darvocet (propoxyphene and acetaminophen) December 5, 2008. Available at: http://www.ashp.org/DocLibrary/Advocacy/Propoxyphene.aspx [Last accessed 2009 June 04]
   Google Scholar
• Miyoshi HR, Leckband SG. Systemic opioid analgesics. In: Loeser JD, ed. Bonica's Management of Pain. Philadelphia: Lippincott, Williams & Wilkins, 2001
   Google Scholar
• Martini L, Whistler JL. The role of mu opioid receptor desensitization and endocytosis in morphine tolerance and dependence. Curr Opin Neurobiol 2007;17:556-64
   PubMed Web of Science ®Google Scholar
• Zuo Z. The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance. Anesth Analg 2005;101:728-34, table of contents
   PubMed Web of Science ®Google Scholar
• Chung S, Pohl S, Zeng J, et al. Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance. J Pharmacol Exp Ther 2006;318:262-7
   PubMed Web of Science ®Google Scholar
• Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999;37:17-40
   PubMed Web of Science ®Google Scholar
• Kieffer BL, Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog Neurobiol 2002;66:285-306
   PubMed Web of Science ®Google Scholar
• Kieffer BL. Opioids: first lessons from knockout mice. Trends Pharmacol Sci 1999;20:19-26
   PubMed Web of Science ®Google Scholar
• Matthes HW, Maldonado R, Simonin F, et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 1996;383:819-23
   PubMed Web of Science ®Google Scholar
• Pasternak GW. Multiple opiate receptors: déjà vu all over again. Neuropharmacology 2004;47:312-23
   PubMed Web of Science ®Google Scholar
• Barkin RL, Iasco AM, Barkin SJ. Opioids used in primary care for the management of pain: a pharmacologic, pharmacotherapeutic, and pharmacodynamic overview. In: Boswell MV, Cole BE, eds. Weiner's Pain Management: A Practical Guide for Clinicians, 7th edn. New York, NY: Taylor & Francis, 2005
   Google Scholar
• Devi LA. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 2001;22:532-7
   PubMed Web of Science ®Google Scholar
• Simonin F, Slowe S, Becker JA, et al. Analysis of [3H]bremazocine binding in single and combinatorial opioid receptor knockout mice. Eur J Pharmacol 2001;414:189-95
   PubMed Web of Science ®Google Scholar
• Simonin F, Valverde O, Smadja C, et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 1998;17:886-97
   PubMed Web of Science ®Google Scholar
• Maldonado R, Negus S, Koob GF. Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta- and kappa-selective opioid antagonists. Neuropharmacology 1992;31:1231-41
   PubMed Web of Science ®Google Scholar
• Leighton GE, Hill RG, Hughes J. Effects of 5-HT and alpha 1 adrenoceptor antagonists on kappa opioid-induced sedation. Pharmacol Biochem Behav 1988;31:899-904
   PubMed Web of Science ®Google Scholar
• Goodman RR, Snyder SH. Kappa opiate receptors localized by autoradiography to deep layers of cerebral cortex: relation to sedative effects. Proc Natl Acad Sci U S A 1982;79:5703-7
   PubMed Web of Science ®Google Scholar
• Knoll AT, Meloni EG, Thomas JB, et al. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 2007;323:838-45
   PubMed Web of Science ®Google Scholar
• Zhu Y, King MA, Schuller AG, et al. Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice. Neuron 1999;24:243-52
   PubMed Web of Science ®Google Scholar
• Nitsche JF, Schuller AG, King MA, et al. Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 2002;22:10906-13
   PubMed Web of Science ®Google Scholar
• Gomes I, Jordan BA, Gupta A, et al. Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 2000;20:RC110
   PubMed Web of Science ®Google Scholar
• Gomes I, Gupta A, Filipovska J, et al. A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci U S A 2004;101:5135-9
   PubMed Web of Science ®Google Scholar
• Jordan BA, Gomes I, Rios C, et al. Functional interactions between mu opioid and alpha 2A-adrenergic receptors. Mol Pharmacol 2003;64:1317-24
   PubMed Web of Science ®Google Scholar
• George SR, Fan T, Xie Z, et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 2000;275:26128-35
   Google Scholar
• Rozenfeld R, Devi LA. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers. FASEB J 2007;21:2455-65
   PubMed Web of Science ®Google Scholar
• Rios C, Gomes I, Devi LA. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 2006;148:387-95
   PubMed Web of Science ®Google Scholar
• Rios CD, Jordan BA, Gomes I, et al. G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther 2001;92:71-87
   PubMed Web of Science ®Google Scholar
• Riley J, Ross JR, Rutter D, et al. A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain. Palliat Med 2004;18:19-24
   PubMed Web of Science ®Google Scholar
• Ross JR, Rutter D, Welsh K, et al. Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 2005;5:324-36
   PubMed Web of Science ®Google Scholar
• Rossi GC, Brown GP, Leventhal L, et al. Novel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesia. Neurosci Lett 1996;216:1-4
   PubMed Web of Science ®Google Scholar
• Chang A, Emmel DW, Rossi GC, et al. Methadone analgesia in morphine-insensitive CXBK mice. Eur J Pharmacol 1998;351:189-91
   PubMed Web of Science ®Google Scholar
• Pan L, Xu J, Yu R, et al. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 2005;133:209-20
   PubMed Web of Science ®Google Scholar
• Pan YX, Xu J, Mahurter L, et al. Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene. Proc Natl Acad Sci U S A 2001;98:14084-9
   PubMed Web of Science ®Google Scholar
• Pan YX, Xu J, Mahurter L, et al. Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun 2003;301:1057-61
   PubMed Web of Science ®Google Scholar
• Bolan EA, Pan YX, Pasternak GW. Functional analysis of MOR-1 splice variants of the mouse mu opioid receptor gene Oprm. Synapse 2004;51:11-18
   PubMed Web of Science ®Google Scholar
• Abbadie C, Gultekin SH, Pasternak GW. Immunohistochemical localization of the carboxy terminus of the novel mu opioid receptor splice variant MOR-1C within the human spinal cord. Neuroreport 2000;11:1953-7
   PubMed Web of Science ®Google Scholar
• Lotsch J, Geisslinger G. Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers. Pharmacogenomics J 2006;6:200-10
   PubMed Web of Science ®Google Scholar
• Oertel B, Lötsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 2008;9:179-94
   PubMed Web of Science ®Google Scholar
• Skorpen F, Laugsand EA, Klepstad P, et al. Variable response to opioid treatment: any genetic predictors within sight?. Palliat Med 2008;22:310-27
   PubMed Web of Science ®Google Scholar
• Klepstad P, Rakvag TT, Kaasa S, et al. The 118A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand 2004;48:1232-9
   PubMed Web of Science ®Google Scholar
• Reyes-Gibby CC, Shete S, Rakvag T, et al. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007;130:25-30
   PubMed Web of Science ®Google Scholar
• Romberg RR, Olofsen E, Bijl H, et al. Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 2005;102:522-30
   PubMed Web of Science ®Google Scholar
• Landau R, Kern C, Columb MO, et al. Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008;139:5-14
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Wieting J, et al. Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 2006;79:72-89
   PubMed Web of Science ®Google Scholar
• Rakvag TT, Klepstad P, Baar C, et al. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;116:73-8
   PubMed Web of Science ®Google Scholar
• Ross JR, Riley J, Taegetmeyer AB, et al. Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects. Cancer 2008;112:1390-403
   PubMed Web of Science ®Google Scholar
• Zubieta JK, Heitzeg MM, Smith YR, et al. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003;299:1240-3
   PubMed Web of Science ®Google Scholar
• Xia Y, Wikberg JE, Chhajlani V. Expression of melanocortin 1 receptor in periaqueductal gray matter. Neuroreport 1995;6:2193-6
   PubMed Web of Science ®Google Scholar
• Mogil JS, Ritchie J, Smith SB, et al. Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans. J Med Genet 2005;42:583-7
   PubMed Web of Science ®Google Scholar
• Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007;81:429-44
   PubMed Web of Science ®Google Scholar
• Evans DA, Mahgoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980;17:102-5
   PubMed Web of Science ®Google Scholar
• Heiskanen T, Kalso E, Olkkola KT. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64:603-11
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Lou YQ, Du YL, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992;51:388-97
   PubMed Web of Science ®Google Scholar
• Bathum L, Johansson I, Ingelman-Sundberg M, et al. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998;8:119-23
   PubMedGoogle Scholar
• Lovlie R, Daly AK, Molven A, et al. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996;392:30-4
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004;43:983-1013
   PubMed Web of Science ®Google Scholar
• Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004;32:447-54
   PubMed Web of Science ®Google Scholar
• Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract 2007;7:352-6
   PubMedGoogle Scholar
• Susce MT, Murray-Carmichael E, de Leon J. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1356-8
   PubMed Web of Science ®Google Scholar
• OxyContin® (oxycodone HCl controlled-release tablets). Full Prescribing Information, Purdue Pharma L.P., Stamford, CT, 2007
   Google Scholar
• Ultram ER® (tramadol hydrochloride). Full Prescribing Information, Ortho-McNeil, Raritan, NJ, 2008
   Google Scholar
• Duragesic® (fentanyl transdermal system). Full Prescribing Information, Janssen Pharmaceuticals, Inc., Titusville, NJ, 2008
   Google Scholar
• Coffman BL, Rios GR, King CD, et al. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 1997;25:1-4
   PubMed Web of Science ®Google Scholar
• Green MD, King CD, Mojarrabi B, et al. Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 1998;26:507-12
   PubMed Web of Science ®Google Scholar
• Bhasker CR, McKinnon W, Stone A, et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000;10:679-85
   PubMedGoogle Scholar
• Coffman BL, King CD, Rios GR, et al. The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 1998;26:73-7
   PubMed Web of Science ®Google Scholar
• Saito K, Moriya H, Sawaguchi T, et al. Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin Biochem 2006;39:303-8
   PubMed Web of Science ®Google Scholar
• Kadian® (morphine sulfate sustained release capsules). Full Prescribing Information, Alpharma, Piscataway, NJ, 2007
   Google Scholar
• OPANA® ER (oxymorphone hydrochloride extended-release tablets). Full Prescribing Information, Endo Pharmaceuticals Inc., Chadds Ford, PA, 2008
   Google Scholar
• Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33
   PubMed Web of Science ®Google Scholar
• Hamabe W, Maeda T, Kiguchi N, et al. Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain. J Pharmacol Sci 2007;105:353-60
   PubMed Web of Science ®Google Scholar
• King M, Su W, Chang A, et al. Transport of opioids from the brain to the periphery by P-glycoprotein: peripheral actions of central drugs. Nat Neurosci 2001;4:268-74
   PubMed Web of Science ®Google Scholar
• Campa D, Gioia A, Tomei A, et al. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008;83:559-66
   PubMed Web of Science ®Google Scholar
• Coller JK, Barratt DT, Dahlen K, et al. ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 2006;80:682-90
   PubMed Web of Science ®Google Scholar
• Park HJ, Shinn HK, Ryu SH, et al. Genetic polymorphisms in the ABCB1 gene and the effects of fentanyl in Koreans. Clin Pharmacol Ther 2007;81:539-46
   PubMed Web of Science ®Google Scholar
• Harrison LM, Grandy DK. Opiate modulating properties of nociceptin/orphanin FQ. Peptides 2000;21:151-72
   PubMed Web of Science ®Google Scholar
• Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev 2001;53:381-415
   PubMed Web of Science ®Google Scholar
• Chia YY, Chow LH, Hung CC, et al. Gender and pain upon movement are associated with the requirements for postoperative patient-controlled iv analgesia: a prospective survey of 2,298 Chinese patients. Can J Anaesth 2002;49:249-55
   PubMed Web of Science ®Google Scholar
• Sidebotham D, Dijkhuizen MR, Schug SA. The safety and utilization of patient-controlled analgesia. J Pain Symptom Manage 1997;14:202-9
   PubMed Web of Science ®Google Scholar
• De Kock M, Scholtes JL. Postoperative P.C.A. in abdominal surgery. Analysis of 200 consecutive patients. Acta Anaesthesiol Belg 1991;42:85-91
   PubMedGoogle Scholar
• Pud D, Yarnitsky D, Sprecher E, et al. Can personality traits and gender predict the response to morphine? An experimental cold pain study. Eur J Pain 2006;10:103-12
   PubMed Web of Science ®Google Scholar
• Sarton E, Olofsen E, Romberg R, et al. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology 2000;93:1245-54; discussion 6A
   PubMed Web of Science ®Google Scholar
• Bolan EA, Tallarida RJ, Pasternak GW. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 2002;303:557-62
   PubMed Web of Science ®Google Scholar
• Hale ME, Ahdieh H, Ma T, et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate-to-severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study. J Pain 2007;8:175-84
   PubMed Web of Science ®Google Scholar
• Hale ME, Dvergsten C, Gimbel J. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo- and active-controlled phase III study. J Pain 2005;6:21-8
   PubMed Web of Science ®Google Scholar
• Cheema B, Lagman R, Walsh D, et al. A prospective study of opioid rotation in pain due to advanced cancer J Cancer Pain Sympt Palliat 2008;2:39-46
   Google Scholar
• Lyss AP, Portenoy RK. Strategies for limiting the side effects of cancer pain therapy. Semin Oncol 1997;24:S16-28-34
   PubMed Web of Science ®Google Scholar
• Bruera E, Neumann CM. Opioid toxicities assessment and management. In: Max MB, ed. Pain 1999-An Updated Review IASP Refresher Course on Pain Management. Seattle: IASP Press, 1999
   Google Scholar
• Cherny NI. Opioid analgesics: comparative features and prescribing guidelines. Drugs 1996;51:713-37
   PubMed Web of Science ®Google Scholar
• Bruera E, Neumann CM. Respective limits of palliative care and oncology in the supportive care of cancer patients. Support Care Cancer 1999;7:321-7
   PubMed Web of Science ®Google Scholar
• Katz N. Abuse-deterrent opioid formulations: are they a pipe dream?. Curr Rheumatol Rep 2008;10:11-18
   PubMedGoogle Scholar
• Koch T, Hollt V. Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther 2008;117:199-206
   PubMed Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P, et al. Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 2004;12:762-6
   PubMed Web of Science ®Google Scholar
• Davis MP, LeGrand SB, Lagman R. Look before leaping: combined opioids may not be the rave. Support Care Cancer 2005;13:769-74
   PubMed Web of Science ®Google Scholar
• Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005;6:107-12
   PubMed Web of Science ®Google Scholar
• Pasternak GW. Incomplete cross tolerance and multiple mu opioid peptide receptors. Trends Pharmacol Sci 2001;22:67-70
   PubMed Web of Science ®Google Scholar
• American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 5th edn. Glenview, IL: American Pain Society, 2003
   Google Scholar
• Moryl N, Santiago-Palma J, Kornick C, et al. Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 2002;96:325-8
   PubMed Web of Science ®Google Scholar
• Smith MT. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites. Clin Exp Pharmacol Physiol 2000;27:524-8
   PubMed Web of Science ®Google Scholar
• Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci 2001;69:409-20
   PubMed Web of Science ®Google Scholar
• Patel S, Roshan VR, Lee KC, et al. A myoclonic reaction with low-dose hydromorphone. Ann Pharmacother 2006;40:2068-70
   PubMed Web of Science ®Google Scholar
• Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol 2004;67:269-76
   PubMed Web of Science ®Google Scholar
• Hassan HE, Myers AL, Lee IJ, et al. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci 2007;96:2494-506
   PubMed Web of Science ®Google Scholar
• Levran O, O'Hara K, Peles E, et al. ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008;17:2219-27
   PubMed Web of Science ®Google Scholar
• Prommer E. Levorphanol: the forgotten opioid. Support Care Cancer 2007;15:259-64
   PubMed Web of Science ®Google Scholar
• Prommer E. Oxymorphone: a review. Support Care Cancer 2006;14:109-15
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34:D668-72
   PubMed Web of Science ®Google Scholar
• Anderson R, Saiers JH, Abram S, et al. Accuracy in equianalgesic dosing. conversion dilemmas. J Pain Symptom Manage 2001;21:397-406
   PubMed Web of Science ®Google Scholar
• Ripamonti C, Groff L, Brunelli C, et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?. J Clin Oncol 1998;16:3216-21
   PubMed Web of Science ®Google Scholar
• National Pharmaceutical Council. Pain: Current Understanding of Assessment, Management, and Treatments; 2001
   Google Scholar